This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Experimental Hematology & Oncology Open Access 28 November 2023
-
High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4+ T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens
Clinical Hematology International Open Access 09 August 2022
-
Quantitative and functional characteristics of circulating and bone marrow PD-1- and TIM-3-positive T cells in treated multiple myeloma patients
Scientific Reports Open Access 30 November 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014; 28: 525–542.
Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252–264.
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568–571.
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563–567.
Rosenblatt J, Avivi I, Vasir B, Uhl L, Katz T, Somaiya P et al. Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation. ASH Annual Meeting Abstracts 2012; 120: 578.
Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007; 110: 296–304.
Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia 2013; 27: 464–472.
Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010; 116: 2286–2294.
Hallett WH, Jing W, Drobyski WR, Johnson BD . Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol Blood Marrow Transpl 2011; 17: 1133–1145.
Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res 2013; 19: 3640–3648.
Kearl TJ, Jing W, Gershan JA, Johnson BD . Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. J Immunol 2013; 190: 5620–5628.
Paiva B, Vidriales MB, Rosinol L, Martinez-Lopez J, Mateos MV, Ocio EM et al. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. Leukemia 2013; 27: 2056–2061.
Radl J, Croese JW, Zurcher C, Van den Enden-Vieveen MH, de Leeuw AM . Animal model of human disease. Multiple myeloma. Am J Pathol 1988; 132: 593–597.
Murillo O, Arina A, Hervas-Stubbs S, Gupta A, McCluskey B, Dubrot J et al. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res. 2008; 14: 6895–6906.
Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA . Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013; 19: 997–1008.
Acknowledgements
This study was supported by the Cooperative Research Thematic Network grants RD12/0036/0058 of the Red de Cancer (Cancer Network of Excellence); Instituto de Salud Carlos III, Spain, Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria (FIS: PI060339; 06/1354; 02/0905; 01/0089/01-02; PS09/01897/01370 and G03/136; Sara Borrell: CD13/00340); and Asociación Española Contra el Cáncer (GCB120981SAN), Spain. The study was also supported internationally by the International Myeloma Foundation Junior Grant Proposal and the Multiple Myeloma Research Foundation research fellow award.
Author Contributions
IM, JFSM, EMO and BP conceived the idea and designed the study. EMO, FE, AGC, AB and JFSM supplied study material or patients. BP and NP analyzed flow-cytometric data. LSS, IAM and IR performed immunophenotypic studies. AA, SL and AR performed mouse experiments. RS and BOO measured mouse serum immunoglobulin titers. BP and AA performed statistical analysis. BP, AA, JFSM and IM analyzed and interpreted the data. BP, AA, JFSM and IM wrote the manuscript. All authors reviewed and approved the manuscript.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary information accompanies this paper on the Leukemia website
Rights and permissions
About this article
Cite this article
Paiva, B., Azpilikueta, A., Puig, N. et al. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Leukemia 29, 2110–2113 (2015). https://doi.org/10.1038/leu.2015.79
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.79
This article is cited by
-
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Experimental Hematology & Oncology (2023)
-
Cancer Stem Cells and the Tumor Microenvironment in Tumor Drug Resistance
Stem Cell Reviews and Reports (2023)
-
Specific binding of plant-expressed anti-PD-L1 monoclonal antibody to multiple myeloma cell line RPMI8226
Plant Biotechnology Reports (2023)
-
High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4+ T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens
Clinical Hematology International (2022)
-
Quantitative and functional characteristics of circulating and bone marrow PD-1- and TIM-3-positive T cells in treated multiple myeloma patients
Scientific Reports (2020)